BOYD GROUP SERVICES INC. ANNOUNCES SECOND QUARTER 2026 CASH DIVIDEND

PR Newswire

WINNIPEG, MB, June 17, 2026 /PRNewswire/ – Boyd Group Services Inc. (TSX: BYD) (NYSE: BGSI) today announced a cash dividend for the second quarter of 2026 of C$0.156 per common share. The dividend will be payable on July 29, 2026 to common shareholders of record at the close of business on June 30, 2026.

Shareholders who are non-residents of Canada will be subject to withholding taxes in respect of any dividends made by Boyd Group Services Inc.

ON BEHALF OF THE BOARD OF DIRECTORS
of Boyd Group Services Inc.

Mr. Brian Kaner, President & CEO

About Boyd Group Services Inc.

Boyd Group Services Inc. (“BGSI”) is a Canadian corporation and controls The Boyd Group Inc. and its subsidiaries. BGSI shares trade on the Toronto Stock Exchange under the symbol BYD and on the New York Stock Exchange under the symbol BGSI.

About The Boyd Group Inc.

The Boyd Group Inc. (“Boyd”) is one of the largest operators of non-franchised collision repair centres in North America in terms of number of locations and sales. Boyd operates locations in Canada under the trade names Boyd Autobody & Glass and Assured Automotive as well as in the U.S. under the trade name Gerber Collision & Glass. In addition, Boyd is a major retail auto glass operator in the U.S. with operations under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority and Autoglassonly.com. Boyd also operates a third-party administrator, Gerber National Claims Services, that offers glass, emergency roadside and first notice of loss services. Boyd also operates a Mobile Auto Solutions (“MAS”) service that offers scanning and calibration services.


Caution concerning forward-looking information

Statements made in this press release constitute “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian and United States securities laws, including the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking information”). Forward-looking information can be generally identified by words such as “may”, “will”, “anticipate”, “estimate”, “expect”, “intend”, “continue”, “should”, “believe” or the negatives thereof and similar variations. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this press release, are subject to known and unknown risks, uncertainties and other factors that may cause the actual results or events to be materially different from those expressed or implied by such forward-looking information, including but not limited to the risks and uncertainties detailed under the “Business Risks and Uncertainties” section of the Company’s current annual information form, the “Business Risks and Uncertainties” and other sections of the Company’s management’s discussion and analysis of operating results and financial position and in the Company’s other periodic filings with the Canadian securities regulatory authorities and the SEC from time to time, available at www.sedarplus.com and www.sec.gov, respectively. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. All forward-looking information presented herein should be considered in conjunction with such filings. Although the Company believes the expectations reflected in such forward-looking information and the assumptions upon which it is based are reasonable, no assurance can be given that actual results will be consistent with such forward-looking information, and it should not be unduly relied upon. There can be no assurance that such expectations and assumptions will prove to be correct. The forward-looking information contained in this press release describes the expectations of the Company as of the date of this press release. Except as required by law, the Company does not undertake to update or revise any forward-looking information contained herein, whether as a result of new information, future events or for any other reason. The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement.

Cision View original content:https://www.prnewswire.com/news-releases/boyd-group-services-inc-announces-second-quarter-2026-cash-dividend-302802616.html

SOURCE Boyd Group Services Inc.

High Tide’s German Subsidiary Remexian Pharma Showcases Exclusive Canadian Medical Cannabis Brand Partnerships at Mary Jane Berlin 2026

PR Newswire

CALGARY, AB, June 17, 2026 /PRNewswire/ – High Tide Inc. (“High Tide” or the “Company”) (NASDAQ: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, announced today that its majority-owned subsidiary, Remexian Pharma GmbH (“Remexian”), showcased its exclusive German medical cannabis distribution partnerships with leading Canadian cannabis brands at Mary Jane Berlin 2026, one of Europe’s largest cannabis trade shows, held June 11–14, 2026, in Berlin, Germany. Through these partnerships, Remexian is bringing premium Canadian medical cannabis products to German patients and pharmacies, further strengthening its position as a leading importer and distributor in one of the world’s fastest-growing medical cannabis markets.

High Tide Inc., June 17, 2026

At the event, Remexian featured medical cannabis products from Tribal, Highly Dutch Organic, Weed Me, The Loud Plug, Joi Botanicals and Castle Rock Farms, highlighting its growing portfolio of exclusive brand distribution agreements and connecting these Canadian brands directly with pharmacies, healthcare professionals, patients and other key stakeholders across Germany’s rapidly expanding medical cannabis ecosystem.

Germany continues to represent one of the most significant growth opportunities in the global medical cannabis industry, and Remexian’s participation in Mary Jane Berlin further reinforces its position as a trusted importer and distributor of premium Canadian medical cannabis products. The event also supported the continued expansion of Remexian’s pharmacy network and strengthened relationships with healthcare professionals and industry participants throughout the country.

“The response we received at Mary Jane Berlin reinforces what we are seeing across the German market: patients and healthcare professionals are actively seeking differentiated, high-quality cannabis products backed by trusted brands. Through Remexian, we are bringing some of Canada’s most recognized and in-demand cannabis brands directly to this growing patient base. We believe our unmatched procurement capabilities and expanding portfolio of exclusive distribution agreements are creating a meaningful competitive advantage in Germany,” said Raj Grover, Founder and Chief Executive Officer of High Tide.

“By continuously broadening our product offering and strengthening relationships across the supply chain, we are positioning Remexian to capture an even larger share of one of the world’s most attractive medical cannabis markets. This is another example of how High Tide is leveraging its Canadian strengths to build a globally diversified cannabis platform with multiple avenues for long-term growth,” Added Mr. Grover

ABOUT HIGH TIDE

High Tide, Inc. is the leading community-grown, retail-forward cannabis enterprise engineered to unleash the full value of the world’s most powerful plant. Its wholly owned subsidiary, Canna Cabana, is the second-largest cannabis retail brand globally. High Tide (HITI) is uniquely-built around the cannabis consumer, with wholly-diversified and fully-integrated operations across all components of cannabis, including:

Retail: Canna Cabana is the largest cannabis retail chain in Canada, with 228 domestic and 1 international location. The Company’s Canadian bricks-and-mortar operations span British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario, holding a growing 12% share of the market. In 2021, Canna Cabana became the first cannabis discount club retailer in the world. The Company also owns and operates multiple global e-commerce platforms offering accessories and hemp-derived CBD products. In 2025, the Company became the first North American cannabis operator to launch a bricks-and-mortar presence in Germany.

Medical Cannabis Distribution: Remexian Pharma GmbH is a leading German pharmaceutical company, with a 14% share of the German medical cannabis market, built for the purpose of importation and wholesale of medical cannabis products at affordable prices. Among all German medical cannabis procurers, Remexian has one of the most diverse reaches across the globe and is licensed to import from 19 countries including Canada.

High Tide consistently moves ahead of the currents, having been named one of Canada’s Top Growing Companies by the Globe and Mail’s Report on Business in 2025 for the fifth consecutive year and was recognized as a top 50 company by the TSX Venture Exchange (the “TSXV”) in 2022, 2024 and 2025. High Tide was also ranked number one in the retail category on the Financial Times list of Americas’ Fastest Growing Companies for 2023. To discover the full impact of High Tide, visit www.hightideinc.com. For investment performance, don’t miss the High Tide profile pages on SEDAR+ and EDGAR.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

CONTACT INFORMATION

Media Inquiries

Omar Khan

Chief Communications and Public Affairs Officer

High Tide Inc.


[email protected]


403-770-3080

Investor Inquiries

Vahan Ajamian

Capital Markets Advisor

High Tide Inc.

[email protected]


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release may contain “forward-looking information” and “forward-looking statements within the meaning of applicable securities legislation. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. The forward-looking statements herein include, but are not limited to, statements regarding: the growth potential for Remexian and the ability to capture further market share. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Although the Company believes that the expectations reflected in these statements are reasonable, such statements are based on expectations, factors, and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company’s control, including but not limited to the risk factors discussed under the heading “Non-Exhaustive List of Risk Factors” in Schedule A to our current annual information form, and elsewhere in this press release, as such factors may be further updated from time to time in our periodic filings, available at www.sedarplus.ca and www.sec.gov, which factors are incorporated herein by reference. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results, or otherwise, or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

High Tide Inc. Logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/high-tides-german-subsidiary-remexian-pharma-showcases-exclusive-canadian-medical-cannabis-brand-partnerships-at-mary-jane-berlin-2026-302802470.html

SOURCE High Tide Inc.

S&P Global Ratings Affirms Ecopetrol’s Global and Stand-Alone Credit Ratings

PR Newswire

BOGOTA, Colombia, June 17, 2026 /PRNewswire/ — Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC, the “Company”) informs that S&P Global Ratings (“S&P”) has affirmed the Company’s global credit rating at BB- with a stable outlook, as well as Ecopetrol’s Stand-Alone Credit Profile (“SACP”) at bb+. The credit rating reflects S&P’s assessment as of the date hereof and is subject to change at any time. A credit rating is not a recommendation to buy, sell, or hold securities and may be revised or withdrawn by S&P at any time.

With respect to the stand-alone rating, S&P highlighted the Company’s continued strengthening of its liquidity sources, noting that Ecopetrol secured a committed credit facility of approximately USD190 million, refinanced its short-term debt maturities, and has benefited from higher operating cash flows.

In addition, according to S&P, the Company is expected to maintain solid leverage metrics, with an adjusted net debt-to-EBITDA ratio close to 2.0x over the coming years, supported by a favorable price environment and no significant debt increases in the short term. These are S&P’s own estimates and do not necessarily reflect the Company’s internal estimates or guidance.

According to S&P, Ecopetrol’s stable outlook remains linked to that of the Republic of Colombia, reflecting the Company’s continued importance to the Colombian economy and its close relationship with the Government of Colombia.

The full report published by S&P is available below:

————————————-

Ecopetrol is the largest company in Colombia and one of the main integrated energy companies in the American continent, with more than 19,000
employees. In Colombia, it is responsible for more than 60% of the hydrocarbon production of most transportation, logistics, and hydrocarbon refining
systems, and it holds leading positions in the petrochemicals and gas distribution segments. With the acquisition of 51.4% of 
ISA’s shares, the company participates in energy transmission, the management of real-time systems (XM), and the BarranquillaCartagena coastal highway concession. At the international level, Ecopetrol has a stake in strategic basins in the American continent, with drilling and exploration operations in the United States (Permian basin and the Gulf of Mexico), Brazil, and Mexico, and, through ISA and its subsidiaries, Ecopetrol holds leading positions in the power transmission business in Brazil, Chile, Peru, and Bolivia, road concessions in Chile, and the telecommunications sector.

This
release contains statements that may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933,
as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All forward-looking statements, whether made in this release or in future filings or press releases, or orally, address matters that involve risks and uncertainties, including in respect of the Company’s prospects for growth and its ongoing access to capital to fund the Company’s business plan, among others. Consequently, changes in the following factors, among others, could cause actual results to differ materially from those included in the forward-looking statements: market prices of oil & gas, our exploration, and production activities, market conditions, applicable regulations, the exchange rate, the Company’s competitiveness and the performance of Colombia’s economy and industry, to mention a few. We do not intend and do not assume any obligation to update these forward-looking statements.

For more information, please contact:


Investor Relations Office


Email

:

 

[email protected]


Head


of Corporate Communications (Colombia)


Marcela Ulloa

Email

:

 

[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sp-global-ratings-affirms-ecopetrols-global-and-stand-alone-credit-ratings-302802528.html

SOURCE Ecopetrol S.A.

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

PR Newswire

SOUTH SAN FRANCISCO, Calif., June 17, 2026 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that its Board of Directors has elected Yujiro S. Hata, Chairman of the Board. Mr. Hata is currently President and Chief Executive Officer, and a member of IDEAYA’s Board. Terry Rosen, Ph.D., will serve as Lead Independent Director of IDEAYA’s Board.

“On behalf of the Board of Directors, I would like to congratulate Yujiro on this Chair appointment,” said Dr. Terry Rosen, Lead Independent Director, IDEAYA Biosciences. “Since founding IDEAYA over a decade ago, Yujiro’s vision, passion for the mission, and leadership have been core to the evolution of IDEAYA from an early science-driven start-up to a leading precision medicine oncology company with an extensive clinical pipeline where commercial launch preparations are underway.”

“I am grateful to the board for the opportunity to serve and advance IDEAYA’s vision to drive forward our important cancer research and deliver breakthrough therapies for patients to address high unmet medical needs in cancer,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to IDEAYA’s vision, strategy, mission, future growth, advancement of its research programs, development and potential commercialization of its product candidates, preparations for potential commercial launches, and the ability to deliver breakthrough therapies to patients with cancer and address unmet medical needs. Such forward-looking statements are based on management’s current expectations, assumptions and beliefs and involve substantial risks and uncertainties that could cause actual results, including, but not limited to, those related to IDEAYA’s clinical programs, commercial activities, and performance and/or achievements, to differ significantly and/or materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the process of designing and conducting preclinical and clinical trials, enrollment rates, safety outcomes, efficacy results, regulatory interactions and decisions, and the ability to translate preclinical findings into clinical benefit, manufacturing and supply risks, competition, changes in standard of care, the timing and success of commercialization efforts, the outcome of collaborations and licensing arrangements, IDEAYA’s ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of financial resources to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. A further description of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, are in IDEAYA’s filings with the Securities and Exchange Commission, including IDEAYA’s most recent Annual Report on Form 10-K and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact

IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-yujiro-s-hata-elected-chairman-of-its-board-of-directors-302802421.html

SOURCE IDEAYA Biosciences, Inc.

POMDOCTOR LIMITED Announces ADS Ratio Change to Be Effective on June 22, 2026

PR Newswire

GUANGZHOU, China, June 17, 2026 /PRNewswire/ — POMDOCTOR LIMITED (the “Company”) (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced that, as previously announced on May 28, 2026, the ratio change of its American depositary shares (the “ADSs”) to Class A ordinary shares from the current ratio of one (1) ADS representing one-sixth (1/6) Class A ordinary share to a new ratio of one (1) ADS representing three (3) Class A ordinary shares (the “ADS Ratio Change”) will become effective on June 22, 2026, U.S. Eastern Time (the “Effective Date”).

For the Company’s ADS holders, the ADS Ratio Change will have the same effect as a one-for-eighteen reverse ADS split. There will be no change to the Company’s Class A ordinary shares. On the Effective Date, holders of ADSs in the Direct Registration System and in The Depository Trust Company will have their ADSs automatically exchanged and need not take any action. The exchange of every eighteen (18) then-held existing ADSs for one (1) new ADS will occur automatically on the Effective Date, with the then-held ADSs being cancelled and new ADSs being issued by Citibank, N.A., the depositary bank for the Company’s ADS program (the “Depositary”).

The Company’s ADSs are expected to begin trading on the Nasdaq Stock Market on a post-reverse ADS split basis under the same ticker symbol “POM” at the market opening on the Effective Date. The new CUSIP number for the Company’s ADSs following the ADS Ratio Change will be 73181R207.

No fractional new ADSs will be issued in connection with the ADS Ratio Change. Instead, fractional entitlements to new ADSs will be aggregated and sold by the Depositary and the net cash proceeds from the sale of the fractional ADS entitlements will be distributed to the applicable ADS holders by the Depositary, in each case in accordance with the Depositary’s then-current procedures and practices and after any deductions as provided in the deposit agreement between the Company and the Depositary for the ADSs.

As a result of the ADS Ratio Change, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the ADS Ratio Change will be equal to or greater than eighteen times the ADS trading price before the change.

About POMDOCTOR LIMITED

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China’s Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company’s operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company’s mission is to provide effective prevention and treatment solutions to alleviate patients’ sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company’s website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED

Investor Relations Department
Email: [email protected]

Ascent Investor Relations LLC

Tina Xiao
Phone: +1-646-932-7242
Email: [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-ads-ratio-change-to-be-effective-on-june-22-2026-302801244.html

SOURCE POMDOCTOR LIMITED

Deep Isolation Nuclear Appoints Drilling Veteran Jon Tedrick to Lead World’s First Full-scale Deep Borehole Disposal Demonstration

Industry veteran relocates to Texas to support field execution of the project as Deep Isolation advances its full-scale demonstration and the next phase of commercialization

BERKELEY, Calif., June 17, 2026 (GLOBE NEWSWIRE) — Deep Isolation Nuclear, Inc. (“Deep Isolation” or the “Company”), a leading innovator in nuclear waste disposal technology, today announced that Technology Demonstration Lead Jon Tedrick has relocated to Texas to support execution of the Company’s demonstration program at the Deep Borehole Demonstration Center (DBDC) near Cameron, Texas. The relocation reflects Deep Isolation’s commitment to establishing a strong field presence as the project progresses toward active operations.

The demonstration program is designed to validate key components of the Company’s deep borehole disposal solution under representative field conditions. Earlier this year, Deep Isolation and its collaborators marked the launch of the project with a groundbreaking ceremony at the DBDC. Through the project, Deep Isolation plans to demonstrate the construction of a deep borehole repository using standard oil and gas drilling practices, full-scale canister emplacement and retrieval operations using its Universal Canister System (UCS), and simulated surface handling operations.

Tedrick’s relocation coincides with Deep Isolation’s recent selection for the U.S. Department of Energy’s ARPA-E SCALEUP Ready program, which is designed to accelerate promising energy technologies toward commercial deployment. The program provides up to $20 million to the Company to support testing and demonstration activities. The Deep Isolation project brings together a world-class team, including Westinghouse, NAC International (TYO: 7004), Halliburton (NYSE: HAL), Occlusion Nuclear Solutions, Amentum (NYSE: AMTM) and the Deep Borehole Demonstration Center, to demonstrate an integrated solution for the storage, transportation and permanent disposal of advanced reactor and nuclear recycling waste.

As Technology Demonstration Lead, Tedrick is responsible for coordinating field execution activities, supporting engagement with project collaborators and contractors, and helping oversee preparations for upcoming demonstration activities at the Cameron site. Tedrick brings more than 28 years of drilling and project management experience spanning mining, geothermal, environmental and energy applications, including leadership of major drilling programs for the U.S. Department of Energy.

“The Cameron demonstration program is an important milestone in our path to commercialization and a critical opportunity to validate our technology at full scale,” said Rod Baltzer, CEO of Deep Isolation. “As we move closer to field execution, having Jon on the ground strengthens on-site coordination and helps ensure we are prepared to successfully deliver this first-of-its-kind demonstration. His extensive drilling and project leadership experience will be invaluable as we advance toward active operations.”

“Throughout my career, I have worked on complex drilling projects across the energy, mining and environmental sectors, but few have combined this level of technical innovation with such an important mission,” said Tedrick. “Relocating to Texas allows me to work closely with our field team as we prepare for the next phase of execution. I am excited to help demonstrate how proven drilling technologies can be applied to address one of the nuclear industry’s most significant challenges.”

As interest in advanced nuclear energy continues to grow, the need for practical, scalable solutions for the management and disposal of spent nuclear fuel and high-level radioactive waste has become increasingly important. Supported by ARPA-E’s SCALEUP Ready program and a consortium of leading industry collaborators, the Cameron project is designed to advance the technical, operational and regulatory foundations needed for future deployment of an integrated solution for the storage, transportation and permanent disposal of advanced reactor and nuclear recycling waste.

About Deep Isolation

Deep Isolation is the first company to undertake development of technologies for nuclear waste disposal in deep boreholes. When commercialized, Deep Isolation’s solution will offer a unique solution to help countries identify, plan for and complete the necessary steps to dispose of their nuclear waste inventories. With over 100 patents issued to date, Deep Isolation’s technology is being designed to leverage proven drilling practices to allow safe isolation of waste deep underground in horizontal, vertical, or slanted borehole repositories. Deep Isolation’s Universal Canister System was developed through a three-year project funded by the U.S. Department of Energy’s Advanced Research Projects Agency–Energy and is engineered to support integrated management of spent fuel and high-level radioactive waste from legacy and advanced reactors across storage, transportation, and eventual disposal. In January 2026, Deep Isolation launched a full-scale, at-depth deep borehole Commercialization Pilot for its solution at Cameron, Texas, in collaboration with the Deep Borehole Demonstration Center, Halliburton (NYSE: HAL), Amentum (NYSE: AMTM), NAC International, and Occlusion Nuclear Solutions.

For more information, visit: https://www.deepisolation.com

Media Contact:

Sophie McCallum
[email protected]

Investor Contact:

Caldwell Bailey
[email protected]

Forward-Looking Statements

Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding our plans, objectives and expectations for our business, the future growth of our business and the nuclear energy and nuclear waste disposal industries as a whole, and future benefits expected to arise from our strategic partnerships. In certain cases, forward-looking statements can be identified by the use of words and phrases or variations of words and phrases or statements such as “may,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,” “could,” “project,” “target,” “potential,” “continue” and similar expressions. Forward-looking statements are based on management’s belief and assumptions, including current expectations and projections about future events and trends, and on information currently available to management.

Forward-looking statements in this or any other news release are subject to a number of risks, uncertainties, and assumptions that could cause actual results to be materially different from those expressed or implied by such forward-looking statements. Such risks, uncertainties, and assumptions are subject to a number of factors, including, among others: the failure of a market to develop for our deep borehole disposal solutions as quickly as we expect or at all; a failure of demand for our solution to develop sufficiently; regulatory and legal developments, including issues relating to obtaining regulatory approvals or permissions on the timelines we expect or at all; our lack of profitability; delays or failure in our initiative to complete a full-scale, at-depth demonstration of our Universal Canister System and our deep borehole solution; our failure to enter into contracts with customers or, once we do enter into contracts, to continue such contractual relationships or to receive new contract awards; our dependency on governmental contracts and awards and our ability to finalize negotiations on same; our failure to manage our growth effectively or to execute our business plan; our failure to sustain and expand relationships with governmental entities and strategic partners; a failure in the assumptions or analyses we have used in supporting forecasts or plans; our inability to commercialize our products at scale; the development or deployment of other technologies or solutions supplanting or competing with our technologies; challenges to our intellectual property; failures to protect, maintain, enforce, and enhance our intellectual property, and claims by others of intellectual property infringement; political and public perceptions of nuclear energy, including perceptions as to accidents or other high-profile events involving nuclear power facilities or radioactive materials; our liquidity and ability to raise capital; any inability to control operating and project costs and project delays or other project-related problems; security (including cybersecurity) breaches or disruptions; geopolitical, macroeconomic, domestic events or crises, including supply chain disruptions and other risks and uncertainties outside of our control; weather and effects of climate change; and litigation or legal proceedings that may be brought against us.

The foregoing is not an exhaustive list of all the factors that may cause any forward-looking statements to prove inaccurate or our actual results to differ materially from our expectations and forecasts. Moreover, we operate in a highly regulated environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements, and we cannot guarantee future results, performance, or achievements. Accordingly, readers should not place undue reliance on forward-looking statements. We undertake no obligation to update any forward-looking statements for any reason after the date of this release or to conform these statements to actual results or revised expectations, except as required by law.

Additional information concerning the factors above and other factors will be found in the Company’s public filings with the Securities and Exchange Commission (the “SEC”), including the sections titled “Forward-Looking Statements” and “Risk Factors” in the Company’s Reports on Form 10-K and 10-Q for the fiscal year ended December 31, 2025 and the quarter ending March 31, 2026, respectively, as filed with the SEC on March 30, 2026, our Form S-1, originally filed August 18, 2025 and subsequently amended, our Proxy Statement for our 2026 Annual Meeting as filed on April 29, 2026, and in filings with the SEC that will be made in the future. The Company’s SEC filings are available free of charge at www.sec.gov or upon written request to Deep Isolation at [email protected] or [email protected].

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/344d17f4-c753-4e58-8a38-1605dc59ab79



Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering


  • Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility

  • Additional proceeds used to pay for the capped call with a premium of 100% and to repurchase $25 million of common stock to reduce potential dilution

  • Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business

SEATTLE, June 17, 2026 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $250 million aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on June 22, 2026, subject to customary closing conditions. Adaptive Biotechnologies also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $45 million aggregate principal amount of notes.

The notes will be senior, unsecured obligations of Adaptive Biotechnologies. The notes will not bear regular interest, and the principal amount of the notes will not accrete. The notes will mature on July 1, 2031, unless earlier repurchased, redeemed or converted. Before April 1, 2031, noteholders will have the right to convert their notes only upon the occurrence of certain events. From and including April 1, 2031, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Adaptive Biotechnologies will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Adaptive Biotechnologies’s election. The initial conversion rate is 41.48 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $24.11 per share of common stock. The initial conversion price represents a premium of approximately 40.0% over the last reported sale price of $17.22 per share of Adaptive Biotechnologies’s common stock on June 16, 2026. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Adaptive Biotechnologies’s option at any time, and from time to time, on or after July 1, 2029 and on or before the 40th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Adaptive Biotechnologies’s common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. In addition, the notes will be redeemable, in whole and not in part, at Adaptive Biotechnologies’s option at any time, if the aggregate principal amount of the notes that remain outstanding is less than 15% of the aggregate principal amount of notes initially issued under the indenture and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the redemption date.

If a “fundamental change” (as defined in the indenture for the notes) occurs, then, subject to a limited exception, noteholders may require Adaptive Biotechnologies to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the applicable repurchase date.

Adaptive Biotechnologies estimates that the net proceeds from the offering will be approximately $290.8 million (or approximately $334.5 million if the initial purchasers fully exercise their option to purchase additional notes), after deducting the initial purchasers’ discounts and commissions and Adaptive Biotechnologies’s estimated offering expenses. Adaptive Biotechnologies intends to use approximately $22.3 million of the net proceeds to fund the cost of entering into the capped call transactions described below. Adaptive Biotechnologies expects to use approximately $25.0 million of the net proceeds to repurchase 1,451,800 shares of its common stock concurrently with the offering in privately negotiated transactions effected through one of the initial purchasers of the notes or its affiliate, as Adaptive Biotechnologies’s agent. Adaptive Biotechnologies intends to use the remainder of the net proceeds from the offering for the repayment of the OrbiMed Purchase Agreement, general corporate purposes and opportunistic initiatives in the MRD business. If the initial purchasers exercise their option to purchase additional notes, then Adaptive Biotechnologies intends to use a portion of the additional net proceeds to fund the cost of entering into additional capped call transactions as described below. The concurrent repurchases of shares of Adaptive Biotechnologies’s common stock described above may result in Adaptive Biotechnologies’s common stock trading at prices that are higher than would be the case in the absence of these repurchases and may have affected the initial terms of the notes, including the initial conversion price.

In connection with the pricing of the notes, Adaptive Biotechnologies has been advised that J. Wood Capital Advisors LLC (“JWCA”), Adaptive Biotechnologies’s financial advisor with respect to the offering, has agreed to purchase approximately $10 million of shares of common stock concurrently with the offering in privately negotiated transactions with institutional investors through one of the initial purchasers or its affiliate (the “JWCA Purchase”).

In connection with the pricing of the notes, Adaptive Biotechnologies entered into privately negotiated capped call transactions with one or more of the initial purchasers or their affiliates or one or more other financial institutions (the “option counterparties”). The capped call transactions will cover, subject to anti-dilution adjustments substantially similar to those applicable to the notes, the number of shares of Adaptive Biotechnologies’s common stock underlying the notes. If the initial purchasers exercise their option to purchase additional notes, then Adaptive Biotechnologies expects to enter into additional capped call transactions with the option counterparties.

The cap price of the capped call transactions will initially be $34.44 per share, which represents a premium of 100% over the last reported sale price of Adaptive Biotechnologies’s common stock of $17.22 per share on June 16, 2026, and is subject to certain adjustments under the terms of the capped call transactions.

The capped call transactions are expected generally to reduce the potential dilution to Adaptive Biotechnologies’s common stock upon any conversion of the notes and/or offset any potential cash payments Adaptive Biotechnologies is required to make in excess of the principal amount of converted notes, as the case may be, upon conversion of the notes. If, however, the market price per share of Adaptive Biotechnologies’s common stock, as measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the capped call transactions.

In connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to Adaptive Biotechnologies’s common stock and/or purchase shares of Adaptive Biotechnologies’s common stock concurrently with or shortly after the pricing of the notes. This activity, as well as the JWCA Purchase, could increase (or reduce the size of any decrease in) the market price of Adaptive Biotechnologies’s common stock or the notes at that time.

In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Adaptive Biotechnologies’s common stock and/or purchasing or selling Adaptive Biotechnologies’s common stock or other securities of Adaptive Biotechnologies in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and (x) are likely to do so during any observation period related to a conversion of notes or following any repurchase of notes by Adaptive Biotechnologies in connection with any fundamental change and (y) may do so following any repurchase of notes by Adaptive Biotechnologies other than in connection with any fundamental change). This activity, as well as the JWCA Purchase, could also cause or avoid an increase or decrease in the market price of Adaptive Biotechnologies’s common stock or the notes, which could affect the ability to convert the notes, and, to the extent the activity occurs during any observation period related to a conversion of notes, it could affect the number of shares and value of the consideration that noteholders will receive upon conversion of the notes.

As described above, Adaptive Biotechnologies intends to use a portion of the net proceeds of the offering to repurchase shares of its common stock concurrently with the pricing of the offering in privately negotiated transactions. These repurchases, and any other repurchases of shares of Adaptive Biotechnologies’s common stock, may increase, or reduce the size of a decrease in, the trading price of Adaptive Biotechnologies’s common stock, and repurchases executed concurrently with the pricing of the offering may have affected the initial terms of the notes, including the initial conversion price.

The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

Forward-Looking Statements

This press release includes forward-looking statements, including statements regarding the completion of the offering, the expected amount and intended use of the net proceeds and the effects of entering into the capped call transactions described above. Forward-looking statements represent Adaptive Biotechnologies’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, the satisfaction of the closing conditions related to the offering and risks relating to Adaptive Biotechnologies’s business, including those described in periodic reports that Adaptive Biotechnologies files from time to time with the SEC. Adaptive Biotechnologies may not consummate the offering described in this press release and, if the offering is consummated, cannot provide any assurances regarding its ability to effectively apply the net proceeds as described above. The forward-looking statements included in this press release speak only as of the date of this press release, and Adaptive Biotechnologies does not undertake to update the statements included in this press release for subsequent developments, except as required by law.

Contact Information

Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
[email protected]

Erica Jones, Associate Corporate Communications Director
206-279-2423
[email protected]



NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes

NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes

FORT MYERS, Fla.–(BUSINESS WIRE)–NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today the pricing of its previously announced private offering of $275 million aggregate principal amount of 0.75% convertible senior notes due 2032 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In addition, NeoGenomics granted the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $41.25 million aggregate principal amount of the notes. The offering is expected to close on June 22, 2026, subject to customary closing conditions.

The notes will be senior, unsecured obligations of NeoGenomics and will bear interest at a rate of 0.75% per year payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2027. The notes will mature on July 1, 2032, unless earlier converted, redeemed or repurchased. Before April 1, 2032, noteholders will have the right to convert their notes in certain circumstances and during specified periods. From and after April 1, 2032, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. NeoGenomics will settle conversions by paying or delivering, as applicable, cash, shares of its common stock, par value $0.001 per share (“common stock”), or a combination of cash and shares of its common stock, at NeoGenomics’ election. The initial conversion rate is 70.6140 shares of common stock per $1,000 principal amount of the notes, which represents an initial conversion price of approximately $14.16 per share of NeoGenomics’ common stock. The initial conversion price represents a premium of approximately 35% to the last reported sale price of $10.49 per share of the common stock on The Nasdaq Capital Market on June 16, 2026.

The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events. The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at NeoGenomics’ option at any time, and from time to time, on or after July 6, 2029 and on or before the 51st scheduled trading day immediately preceding the maturity date, if the last reported sale price per share of NeoGenomics’ common stock equals or exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, the notes will be redeemable at any time if the aggregate principal amount of the notes that remains outstanding is less than 15% of the aggregate principal amount of the notes initially issued in the offering and certain other conditions are satisfied.

In connection with the pricing of the notes, NeoGenomics entered into privately negotiated capped call transactions with certain financial institutions (the “option counterparties”). The capped call transactions are expected generally to reduce potential dilution to NeoGenomics’ common stock upon conversion of any notes and/or offset any potential cash payments NeoGenomics is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. The cap price of the capped call transactions will initially be $20.98 per share of NeoGenomics’ common stock, which represents a premium of 100% to the last reported sale price of $10.49 per share of the common stock on The Nasdaq Capital Market on June 16, 2026.

NeoGenomics has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to purchase shares of NeoGenomics’ common stock and/or enter into various derivative transactions with respect to NeoGenomics’ common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of NeoGenomics’ common stock or the notes at that time. In addition, the option counterparties and/or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to NeoGenomics’ common stock and/or purchasing or selling NeoGenomics’ common stock or other securities of NeoGenomics in secondary market transactions from time to time prior to the maturity of the notes (and are likely to do so during any observation period related to a conversion of notes or following certain repurchases or redemptions of the notes). This activity could cause or avoid an increase or a decrease in the market price of NeoGenomics’ common stock or the notes, which could affect the ability of holders to convert the notes and, to the extent the activity occurs following conversion or during any observation period related to a conversion of notes, it could affect the amount and value of the consideration that holders will receive upon conversion of such notes.

NeoGenomics estimates that the net proceeds from the offering of the notes will be approximately $266.15 million (or approximately $306.16 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers’ discounts and commissions and estimated offering expenses payable by NeoGenomics. NeoGenomics intends to use approximately $25 million of the net proceeds from the offering to pay the cost of the capped call transactions. If the initial purchasers exercise their option to purchase additional notes, NeoGenomics expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions. In addition, NeoGenomics intends to use a portion of the net proceeds from the offering, together with cash on hand, to repurchase for cash $276 million aggregate principal amount of NeoGenomics’ 0.25% convertible senior notes due 2028 (the “existing notes”) through privately negotiated transactions entered into concurrently with the pricing of the notes effected through one or more of the initial purchasers or their affiliates as our agents, and the remaining net proceeds from the offering, if any, together with cash on hand, to repurchase up to an aggregate of $25 million of our outstanding shares of common stock from certain purchasers of notes in privately negotiated transactions, effected through one or more of the initial purchasers or their respective affiliates as our agent, entered into concurrently with the closing of this offering, and the remainder of the net proceeds, if any, for general corporate purposes.

The concurrent repurchases of the existing notes and shares of the Company’s common stock described above may result in the Company’s common stock trading at prices that are higher than would be the case in the absence of these repurchases, which may result in a higher initial conversion price for the notes to be offered.

Concurrently with the pricing of the notes, NeoGenomics entered into privately negotiated transactions (the “note repurchase transactions”) with certain holders of the existing notes to repurchase for cash $276 million aggregate principal amount of the existing notes for a total repurchase cost (including accrued and unpaid interest) of approximately $263.19 million. The terms of the note repurchase transactions were individually negotiated with certain holders of the existing notes and depended on a variety of factors, including the market price of NeoGenomics’ common stock and the trading price of the existing notes. This press release is not an offer to repurchase the existing notes, and the offering of the notes is not contingent upon the repurchase of the existing notes.

In connection with the note repurchase transactions, NeoGenomics expects that holders of the existing notes who have agreed to have their existing notes repurchased and who have hedged their equity price risk with respect to such existing notes (the “hedged holders”) will unwind all or part of their hedge positions by buying NeoGenomics’ common stock and/or entering into or unwinding various derivative transactions with respect to NeoGenomics’ common stock. The amount of NeoGenomics’ common stock to be purchased by the hedged holders or the notional number of shares of NeoGenomics’ common stock underlying such derivative transactions may be substantial in relation to the historic average daily trading volume of NeoGenomics’ common stock. This activity by the hedged holders could increase (or reduce the size of any decrease in) the market price of NeoGenomics’ common stock, including concurrently with the pricing of the notes, resulting in a higher effective conversion price of the notes. NeoGenomics cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or NeoGenomics’ common stock and the corresponding effect on the initial conversion price of the notes.

The notes were offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold absent registration or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

About NeoGenomics

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the U.S. and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

Forward Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements, which include those concerning whether NeoGenomics will issue the notes; whether the note repurchase transactions will settle; whether the common stock repurchase transactions will settle; the anticipated use of the net proceeds from the offering; expectations regarding the effect of the capped call transactions; expectations regarding actions of the hedged holders, the option counterparties and their respective affiliates; and whether the capped call transactions will become effective, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, risks with respect to the market acceptance of the Company’s products and services, as well as the risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company’s other filings with the Securities and Exchange Commission (SEC).

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and in the “Investors” section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Investor Contact

[email protected]

Media Contact

Andrea Sampson

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Research Medical Devices Genetics Other Health Biotechnology Pharmaceutical Health Science Oncology Other Science

MEDIA:

Logo
Logo

Ouster and AIM Intelligent Machines Announce Strategic Agreement for Digital Lidar to Equip AI-Powered Heavy Earthmoving Equipment Following the Release of REV8 with Native Color

Ouster and AIM Intelligent Machines Announce Strategic Agreement for Digital Lidar to Equip AI-Powered Heavy Earthmoving Equipment Following the Release of REV8 with Native Color

SAN FRANCISCO–(BUSINESS WIRE)–Ouster, Inc. (Nasdaq: OUST) (“Ouster” or the “Company”), a leader in sensing and perception for Physical AI, and AIM Intelligent Machines (“AIM”), an AI platform for autonomous heavy earthmoving equipment, announced today a strategic agreement for Ouster digital lidar sensors, which will be used to retrofit heavy machines into AI-powered fleets that deliver maximum safety and productivity at mining, construction, and defense sites globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617199530/en/

Ouster digital lidar on AIM's AI platform for autonomous heavy earthmoving equipment.

Ouster digital lidar on AIM’s AI platform for autonomous heavy earthmoving equipment.

The agreement marks a commercial expansion of a multi-year collaboration between the two companies. As AIM scales the deployment of its field-proven autonomy kits to deliver on key customer contracts and meet growing market demand, the strategic agreement guarantees a high-volume supply of Ouster’s high-resolution digital lidar sensors.

Building upon this commercial momentum, AIM plans to integrate Ouster’s new Rev8 native color digital lidar into the AIM AI platform to further advance the perception capabilities of its next-generation automated machinery with precise 3D structural data, color point clouds, and industrial-grade imagery to safely accelerate autonomous operations in the complex, unstructured environments. For AIM, the benefits of Rev8 translate to faster edge-computing, streamlined sensor fusion, and significantly enhanced safety and object-classification capabilities in real-time, high-dust industrial workflows.

“True environmental understanding is foundational to safe and effective earth-moving autonomy,” said Ross Walker, Head of Product at AIM Intelligent Machines. “Ouster’s digital lidar has been foundational in our autonomy stack, helping us achieve a zero-accident safety record across all global deployments. Our strategic agreement allows us to scale the deployment of AI-powered fleets today, while the new Rev8 native color lidar will enable us to enhance the capabilities of our platform for future programs, delivering the human-like sight and spatial precision required with a single sensor.”

AIM’s non-invasive autonomy kit retrofits existing heavy machinery in under 24 hours without voiding OEM warranties. The rugged hardware package pairs an armored enclosure housing a single Ouster digital lidar with machine-angle sensors and a localized edge computer with onboard end-to-end reinforcement learning. Operating completely independent of cellular networks, cloud infrastructure, or GPS signals, the platform ensures peak safety in total darkness, dust storms, and remote, infrastructure-denied environments while supporting manual operator override at any time.

“As heavy industry, mining, and logistics rapidly transition toward autonomous operations, highly reliable, high-resolution 3D perception is paramount,” said Cyrille Jacquemet, Chief Revenue Officer of Ouster. “We are thrilled to deepen our relationship with AIM Intelligent Machines as they scale their AI-powered fleets for heavy equipment and explore the transformative potential of our new Rev8 family. By embedding our native color digital lidar into their intelligent platforms, AIM can redefine what automated machines can see, interpret, and achieve safely at scale.”

About AIM

AIM transforms heavy machines into AI-powered fleets to turbocharge earthmoving across production sites. The AIM AI platform turns bulldozers and excavators into fully autonomous machines that achieve maximum safety and productivity at mining, construction, and defense sites globally. Built by engineers from mining, construction, Waymo, SpaceX, Google and Tesla, AIM enables scalable earthmoving for resource extraction, critical infrastructure, and planetary terraforming. The global economy is reliant on the movement of materials. Therefore, safe autonomous earthmoving is the linchpin of our civilization. For more information, visit www.aim.vision.

About Ouster

Ouster (Nasdaq: OUST) is a leader in sensing and perception for Physical AI across industrial, robotics, automotive, and smart infrastructure. With a unified platform of high-performance digital lidar, cameras, AI compute, sensor fusion and perception software, and AI models, Ouster delivers solutions that improve quality of life in the physical world. Headquartered in San Francisco, CA, Ouster has a global presence serving thousands of customers with offices in the Americas, Europe, and Asia-Pacific. For more information about our products, visit www.ouster.com, contact our sales team, or connect with us on X or LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based upon current plans, estimates and expectations of management that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as “offer,” “expect,” “will”, “may,” “anticipate,” “intend,” “reflect,” “should,” “plan,” “can,” “could,” “estimate,” “possible,” “potential,” “pursue,” “demonstrate,” and the negative of these terms and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All statements, other than historical facts, including statements regarding the capabilities of Ouster’s products, including with respect to the opportunity to improve safety and productivity at mining, construction, and defense sites with Rev8 lidar sensors; uses for Physical AI; the Company’s current expectations and projections relating to future results of operations, plans and objectives; the anticipated performance of Ouster’s products and our expectations around customers’ adoption and application of our products constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including, but not limited to, the substantial research and development costs to develop and commercialize new products; the possibility of cancellation or postponement of contracts or unsuccessful implementations; product quality and liability risks; the Company’s dependence on key third party suppliers, including Benchmark Electronics, Inc.; the Company’s ability to manage growth; risks related to international operations; inaccurate forecasts of market growth and customer demand; Ouster’s ability to respond to evolving regulations and standards; and other important risk factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and as may be further updated from time to time in the Company’s Quarterly Reports on Form 10-Q and other filings with the SEC. Readers are urged to consider these factors carefully and in the totality of the circumstances when evaluating these forward-looking statements, and not to place undue reliance on any of them. Any such forward-looking statements represent management’s reasonable estimates and beliefs as of the date of this press release. While Ouster may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, other than as may be required by law, even if subsequent events cause its views to change.

Ouster:

For Investors

[email protected]

For Media

[email protected]

AIM:

For Media

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Robotics Engineering Technology Manufacturing Software Artificial Intelligence

MEDIA:

Photo
Photo
Ouster digital lidar on AIM’s AI platform for autonomous heavy earthmoving equipment.
Photo
Photo
Ouster digital lidar on AIM’s AI platform for autonomous heavy earthmoving equipment.
Logo
Logo

Franklin BSP Realty Trust, Inc. Announces Second Quarter 2026 Common Stock Dividend of $0.20 Per Share and Series E Cumulative Redeemable Preferred Stock Dividend of $0.46875 Per Share

Franklin BSP Realty Trust, Inc. Announces Second Quarter 2026 Common Stock Dividend of $0.20 Per Share and Series E Cumulative Redeemable Preferred Stock Dividend of $0.46875 Per Share

NEW YORK–(BUSINESS WIRE)–Franklin BSP Realty Trust, Inc. (NYSE: FBRT) (“FBRT” or the “Company”) today announced its Board of Directors has declared a second quarter 2026 dividend of $0.20 per common share. The dividend is payable on or about July 10, 2026, to common stockholders of record as of June 30, 2026. The Board of Directors has also declared a second quarter 2026 dividend on its convertible Series H Preferred Stock in an amount equal to the as-converted common dividend amount.

FBRT’s Board of Directors also declared a second quarter 2026 dividend of $0.46875 per share on its 7.50% Series E Cumulative Redeemable Preferred Stock (NYSE: FBRTPRE). This dividend is payable on July 15, 2026, to Series E preferred stockholders of record as of June 30, 2026.

About Franklin BSP Realty Trust, Inc.

Franklin BSP Realty Trust, Inc. (NYSE: FBRT) is a real estate investment trust that originates, acquires and manages a diversified portfolio of commercial real estate debt secured by properties located in the United States. As of March 31, 2026, FBRT had approximately $6.3 billion of assets. FBRT is externally managed by Benefit Street Partners L.L.C., a wholly owned subsidiary of Franklin Resources, Inc. For further information, please visit www.fbrtreit.com.

About Benefit Street Partners

Benefit Street Partners (BSP) is an alternative credit pioneer with $93 billion in assets under management (including Apera) as of March 31, 2026. It seeks to deliver attractive, risk-adjusted returns through its deep specialism, long-term relationships and global reach. A wholly owned subsidiary of Franklin Templeton, BSP is focused exclusively on credit. Through its disciplined, solutions-oriented approach, BSP unlocks opportunities across market cycles and geographies. The firm manages strategies spanning private debt, real estate debt, structured credit, and liquid loans. For more information, visit bspcredit.com.

About Franklin Templeton

Franklin Templeton is a trusted investment partner, delivering tailored solutions that align with clients’ strategic goals. With deep portfolio management expertise across public and private markets, we combine investment excellence with cutting-edge technology. Since our founding in 1947, we have empowered clients through strategic partnership, forward-looking insights, and continuous innovation – providing the tools and resources to navigate change and capture opportunity.

With more than $1.74 trillion in assets under management as of April 30, 2026, Franklin Templeton operates globally in more than 35 countries.

To learn more, visit franklintempleton.com and follow us on LinkedIn.

Forward-Looking Statements

Certain statements included in this press release are forward-looking statements. Those statements include statements regarding the intent, belief or current expectations of the Company and members of our management team, as well as the assumptions on which such statements are based, and generally are identified by the use of words such as “may,” “will,” “seeks,” “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “should” or similar expressions. Actual results may differ materially from those contemplated by such forward-looking statements. Further, forward-looking statements speak only as of the date they are made, and we undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required by law.

The Company’s forward-looking statements are subject to various risks and uncertainties. Factors that could cause actual outcomes to differ materially from our forward-looking statements include macroeconomic factors in the United States including inflation, changing interest rates and economic contraction, the extent of any recoveries on delinquent loans, the financial stability of our borrowers and the other, risks and important factors contained and identified in the Company’s filings with the Securities and Exchange Commission (“SEC”), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its subsequent filings with the SEC, any of which could cause actual results to differ materially from the forward-looking statements. The forward-looking statements included in this communication are made only as of the date hereof.

Investor Relations Contact:
Lindsey Crabbe
Executive Director, BSP
[email protected]
214-874-2339

Media Contact :
Sam Turvey
Global Head of Communications, BSP
[email protected]
+44 (0) 782 783 6246

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Commercial Building & Real Estate Finance Construction & Property REIT Banking

MEDIA: